Introduction: When Cancer Treatment Became More Personal
For decades, cancer treatment was largely organized around one question: Where did the cancer start?
Was it breast cancer, lung cancer, colorectal cancer, leukemia or another type?
That question is still extremely important. But modern cancer research has added another layer: What is actually driving this particular tumor?
Two people may have cancer in the same organ but have very different genetic changes, proteins, immune characteristics and treatment responses. This growing understanding has helped move oncology toward precision cancer medicine—an approach that uses information about a person’s tumor to help guide diagnosis, prognosis and treatment.
Imagine two patients with the same broad cancer diagnosis. Traditional classification may place them in the same treatment category. Molecular testing, however, could reveal that one tumor carries a change that can be targeted by a specific medicine, while the other does not.
That is the promise of precision oncology.
It does not mean that every cancer patient receives a completely unique drug. It does not mean chemotherapy, surgery or radiation have become obsolete. And it does not guarantee a cure.
Instead, precision cancer medicine aims to make treatment decisions more informed and more closely matched to the biology of a patient’s disease.
For patients and families in India and around the world, this shift could influence how cancer is diagnosed, discussed and treated.
1. What Is Precision Cancer Medicine?
Precision cancer medicine is an approach that uses information about a person’s cancer—including genes, proteins and other biomarkers—to help doctors select treatments that are more likely to benefit that particular patient. It is also called personalized medicine or precision oncology.
Traditional cancer care already considers important factors such as cancer type, stage, tumor size and whether the disease has spread.
Precision medicine adds another layer of information.
Doctors may examine characteristics of cancer cells to determine whether a particular treatment could be useful. These characteristics can include:
- Gene mutations
- Gene fusions
- Protein expression
- DNA repair changes
- Immune-related markers
- Tumor mutational burden
- Other molecular characteristics
The goal is not simply to find “the cancer gene.” Cancer is much more complicated than that.
A tumor can contain multiple genetic and molecular changes, and those changes can evolve during treatment.
Example
A patient with advanced cancer may undergo tumor profiling. The test identifies a molecular alteration associated with a therapy. The oncology team can then consider whether that treatment is appropriate based on the patient’s complete clinical situation.
Practical tip: Ask your oncologist whether biomarker testing is appropriate for your cancer type and stage rather than assuming every patient needs the same genomic test.
2. Why Is Precision Oncology Changing Cancer Treatment?
Precision oncology is changing cancer treatment because researchers increasingly understand that cancers with the same name can behave differently at the molecular level. Identifying these differences can help doctors match selected patients with targeted therapies or immunotherapies and avoid treatments that are unlikely to help.
Cancer develops through biological changes that allow abnormal cells to grow, survive and spread.
Some changes act like growth signals. Others help cancer cells avoid the immune system or repair damaged DNA.
Scientists have spent decades studying these mechanisms.
As molecular biology, genomic sequencing and laboratory technologies improved, researchers gained increasingly detailed information about tumors.
This created a new possibility:
Instead of treating cancer only according to its location, doctors could sometimes treat it according to its molecular characteristics.
The concept has already produced important examples. Some targeted treatments are designed for cancers with particular molecular alterations, while some immunotherapies are selected using biomarkers that indicate whether a patient may be more likely to respond.
Practical takeaway
Precision medicine does not replace clinical judgment. Molecular information is interpreted alongside the patient’s cancer type, stage, overall health, previous treatment and preferences.
3. What Are Biomarkers and Why Do They Matter?
A biomarker is a measurable characteristic that can provide information about cancer or how it may respond to treatment. Biomarker testing can examine genes, proteins and other substances in tumor cells. These results may help doctors choose therapies for selected patients.
Think of biomarkers as biological clues.
For example, a tumor may contain:
- A specific gene alteration
- An abnormal protein
- A gene fusion
- A DNA-repair deficiency
- A characteristic immune marker
Some biomarkers are associated with particular treatments.
However, a biomarker does not automatically mean a treatment will work.
Cancer biology is complex, and treatment decisions require interpretation by qualified oncology professionals.
Biomarker testing vs genetic testing
These terms can be confusing.
Tumor biomarker testing generally looks at characteristics of the cancer.
Inherited genetic testing looks for genetic changes a person was born with that may increase their risk of developing certain cancers.
NCI emphasizes that these are different types of testing.
Practical tip: If a doctor recommends “genetic testing,” ask whether the test is examining the tumor, inherited DNA, or both.
4. How Does Genomic Testing Work?
Genomic testing usually involves analyzing a sample of cancer tissue, often obtained through biopsy or surgery. Depending on the situation, blood-based testing known as liquid biopsy may also be considered. The laboratory analyzes genetic or molecular characteristics and produces a report that the oncology team interprets.
A simplified precision-oncology pathway looks like this:
Cancer diagnosis → tissue/sample collection → laboratory analysis → biomarker report → oncology interpretation → treatment decision
Testing can range from looking for one specific biomarker to analyzing many genes at once.
Some tests use multigene panels, while more comprehensive approaches may examine large portions of the tumor’s genetic material.
What happens after testing?
The report may identify:
- A biomarker with an approved treatment
- A biomarker associated with a possible treatment
- A finding that may be relevant to a clinical trial
- A biomarker with no currently actionable treatment
- No significant alteration identified by the particular test
A “negative” result does not mean that cancer treatment options have disappeared.
Practical tip: Ask your oncologist what the test was designed to find and whether the result could change your treatment plan.
5. Targeted Therapy: Treating Specific Cancer Vulnerabilities
Targeted therapy works by interfering with specific proteins or biological processes that help cancer cells grow, divide or spread. Many targeted therapies are small-molecule drugs or monoclonal antibodies, and biomarker testing may be used to determine whether a tumor contains the relevant target.
This is one of the clearest examples of precision cancer medicine.
Traditional chemotherapy often affects rapidly dividing cells, including cancer cells and some healthy cells.
Targeted therapy is designed around particular biological vulnerabilities.
Depending on the medicine, it may:
- Block growth signals
- Interfere with proteins needed for cancer-cell survival
- Prevent blood-vessel formation
- Help the immune system recognize cancer cells
- Deliver treatment more specifically toward cells carrying a target
NCI notes that targeted therapies are the foundation of precision medicine and that tumor testing is often needed to identify relevant targets.
Important limitation
Not every tumor has an actionable target.
And even when a target exists, the treatment may not work indefinitely because cancer cells can develop resistance.
Practical tip: Ask whether a proposed targeted treatment has been specifically studied for your cancer type and biomarker.
6. Precision Immunotherapy: Using the Immune System
Immunotherapy helps the body’s immune system recognize or attack cancer. Some immunotherapies are selected using biomarkers that can indicate whether a patient may be more likely to respond. Researchers are also studying ways to predict response and overcome resistance.
Cancer cells can develop ways to avoid immune detection.
Some immunotherapies work by removing certain “brakes” on immune cells, allowing them to attack cancer more effectively.
Other approaches involve transferring or modifying immune cells.
Precision medicine has also produced tumor-agnostic treatments, where a treatment may be considered based on a particular molecular characteristic rather than only the organ where the cancer began. NCI describes several biomarker-based tissue-agnostic treatment approaches.
One landmark example involved pembrolizumab for certain tumors with MSI-H or dMMR characteristics, demonstrating how a molecular feature could guide treatment across different tumor origins.
But immunotherapy is not suitable for everyone
Only a portion of patients respond to particular immunotherapies, and researchers continue to investigate why.
Practical tip: If immunotherapy is being considered, ask which biomarker or clinical evidence supports its use in your specific situation
7. Precision Medicine vs Traditional Cancer Treatment
Precision medicine and conventional cancer treatment are not competing systems. Modern oncology often combines them. Surgery, radiation, chemotherapy, hormone therapy, targeted therapy and immunotherapy may all have roles depending on the cancer and patient.
| Approach | Main principle | Possible role |
|---|---|---|
| Surgery | Remove cancer physically | Localized cancers |
| Radiation | Damage cancer cells with radiation | Local/regional control |
| Chemotherapy | Attack rapidly dividing cells | Many cancer settings |
| Hormone therapy | Block hormone-driven cancer growth | Selected cancers |
| Targeted therapy | Attack specific molecular targets | Biomarker-selected cancers |
| Immunotherapy | Activate or improve immune attack | Selected cancers |
| Precision medicine | Use biological information to guide decisions | Across selected cancer settings |
The choice may involve several approaches rather than just one.
Example
A patient could undergo surgery followed by additional treatment. Molecular testing might then help determine whether targeted therapy or another systemic treatment is appropriate.
Practical tip: Ask your cancer team to explain how each proposed treatment fits into the overall treatment strategy.
8. What Happens When Cancer Develops Treatment Resistance?
Cancer can change over time. A treatment that initially works may become less effective if cancer cells develop or select for biological changes that allow them to survive. Precision oncology researchers are studying repeat testing, combination therapies and new molecular targets to address resistance.
Treatment resistance is one of the biggest challenges in modern oncology.
Imagine a tumor containing millions of cancer cells. They may not all be biologically identical.
Treatment can kill cells that are sensitive to a particular therapy while resistant cells survive and multiply.
This can lead to disease progression.
Researchers are therefore studying:
- New biomarkers
- Combination treatments
- Sequential treatments
- Repeat tumor profiling
- Liquid biopsy
- New targeted therapies
- Immune-based combinations
The NCI’s precision medicine research programs, including NCI-MATCH and newer MATCH-related studies, are designed to investigate treatment strategies based on molecular alterations and immune characteristics.
Practical tip: If cancer returns or progresses, ask whether additional molecular testing could provide useful information.
9. Can Liquid Biopsy Make Precision Cancer Care Easier?
Liquid biopsy analyzes cancer-related material found in blood or other body fluids rather than relying only on a tissue biopsy. It may be useful in selected situations, including when obtaining tumor tissue is difficult. However, liquid biopsy does not replace every conventional biopsy or cancer test.
Tumor cells can release fragments of DNA into the bloodstream.
A blood sample can sometimes be analyzed for these molecular signals.
Potential advantages include:
- Less invasive sampling
- Ability to obtain information when tissue is difficult to access
- Potential usefulness in monitoring molecular changes
- Possible role in treatment selection
But there are limitations.
A blood test may not detect every alteration present in a tumor. Results also need clinical interpretation.
NCI notes that liquid biopsy can be considered in situations where a tumor biopsy cannot safely be performed, among other uses.
Practical tip: Do not assume a liquid biopsy is automatically better than tissue testing. Ask which method is most appropriate for your cancer.
10. What Does Precision Cancer Medicine Mean for Patients in India?
In India, precision cancer medicine is becoming increasingly relevant as oncology centers and laboratories use molecular testing to support selected treatment decisions. However, access, availability, cost, test quality and clinical interpretation can vary. Patients should discuss whether testing is appropriate and actionable before ordering expensive genomic panels.
India has a large and diverse cancer burden, making access to effective diagnosis and treatment especially important.
Precision oncology can potentially help identify patients who may benefit from biomarker-guided therapies. But access is not uniform.
Important considerations include:
- Availability of validated testing
- Quality of the laboratory
- Turnaround time
- Cost
- Insurance or reimbursement
- Availability of matching treatment
- Availability of clinical trials
- Expertise of the oncology team
- Interpretation of complex genomic reports
A major mistake is to think that more genomic information always means better treatment.
The value of testing depends on whether the result can actually influence clinical management.
For patients in cities such as Delhi, Mumbai, Bengaluru, Chennai, Hyderabad or Varanasi
Patients may have access to different combinations of oncology hospitals, pathology laboratories, genomic testing services and specialist consultations.
But location alone does not determine the quality of care.
Practical tip: Before ordering a genomic panel, ask your oncologist:
“If this test finds an alteration, what treatment decision could change?”
That question can help distinguish useful testing from testing that may simply produce a long report.
11. What Are the Benefits and Limitations of Precision Oncology?
Precision oncology can help identify treatments for selected biomarker-positive cancers and may reduce the use of therapies unlikely to benefit a particular patient. However, it has limitations, including uncertain findings, treatment resistance, testing costs, unequal access and the fact that many detected alterations do not have an available treatment.
Potential benefits
- More informed treatment selection
- Identification of actionable biomarkers
- Potential access to targeted therapies
- Better understanding of tumor biology
- Possible clinical-trial matching
- More personalized treatment planning
Important limitations
- Not every cancer has an actionable biomarker
- Testing can be expensive
- Results can be difficult to interpret
- Treatments can have significant side effects
- Cancer can develop resistance
- A biomarker does not guarantee response
- Access varies between healthcare settings
NCI specifically notes that precision medicine is advancing but is not yet routine for every cancer patient.
That distinction is essential.
Precision medicine is powerful, but it is not magic.
12. How Can Patients Make Better Decisions About Precision Cancer Testing?
Patients should discuss precision testing with their oncology team before ordering a test. The key questions are whether the test is appropriate for the cancer type and stage, what biomarkers it will assess, whether the results could change treatment, how reliable the laboratory is and whether a matching treatment or clinical trial is available.
Questions to ask your oncologist
- Is biomarker testing recommended for my cancer?
- What biomarkers are you looking for?
- Will the test use tumor tissue or blood?
- Could the result change my treatment?
- Is there an approved treatment for a possible finding?
- Could it help identify a clinical trial?
- How much will the test cost?
- How long will results take?
- Which laboratory will perform the test?
- Who will interpret the report?
This conversation can prevent unrealistic expectations.
A precision test should ideally answer a meaningful clinical question.
From Laboratory Discovery to Patient Treatment: The Precision Oncology Journey
The development of precision cancer medicine follows a long pathway:
Laboratory research
↓
Scientists identify a biological mechanism
↓
A potential biomarker or treatment target is discovered
↓
Laboratory and preclinical research
↓
Clinical trials evaluate safety and effectiveness
↓
Regulatory review and approval where appropriate
↓
Biomarker testing identifies eligible patients
↓
Oncologists interpret the results
↓
Treatment is selected
↓
Response is monitored
↓
Research continues
This is why a promising laboratory discovery should not immediately be described as a proven cancer treatment.
Clinical trials remain essential.
ASCO has emphasized the continuing importance of early-phase clinical trials in developing new molecularly targeted therapies and determining appropriate doses and safety.
Precision Cancer Medicine and the Future of Oncology
The future of precision oncology is likely to involve increasingly detailed information about tumors.
Researchers are exploring:
- More comprehensive genomic profiling
- Liquid biopsy
- Artificial intelligence
- Multi-omics analysis
- Better immune biomarkers
- Combination therapies
- Drug resistance monitoring
- Tumor-agnostic treatments
- Personalized clinical trials
The goal is not simply to generate more data.
The real goal is to turn useful biological information into better clinical decisions.
This distinction matters because a genomic report can contain dozens of findings, but only some may have established clinical significance.
Future oncology systems may become better at identifying which findings matter most.
Why Choose Evidence-Based Precision Cancer Care?
Precision oncology is not a single product or service. It is a multidisciplinary approach involving:
- Medical oncologists
- Surgical oncologists
- Radiation oncologists
- Pathologists
- Molecular laboratories
- Genetic counselors where appropriate
- Radiologists
- Pharmacists
- Clinical researchers
A strong precision-care pathway should prioritize:
Validated testing + expert interpretation + evidence-based treatment + patient-centered decision-making.
Patients should be cautious about companies or services promising that a genomic test can “guarantee” the right cancer treatment.
No responsible test can guarantee that a cancer will respond.
NCI explains that biomarker testing can help doctors select treatments, but the results must be considered alongside the patient’s complete clinical situation.
Frequently Asked Questions About Precision Cancer Medicine
What is precision cancer medicine?
Precision cancer medicine uses information about a person’s tumor—including genetic, protein and other molecular characteristics—to help guide diagnosis, prognosis and treatment decisions. It may involve biomarker testing and can help identify patients who may benefit from targeted therapies or selected immunotherapies.
Is precision medicine the same as personalized medicine?
The terms are often used interchangeably. Both describe approaches that use individual biological or clinical information to guide medical decisions. In oncology, precision medicine commonly refers to using tumor characteristics and biomarkers to help select treatment.
Does every cancer patient need genomic testing?
No. The usefulness of genomic or biomarker testing depends on cancer type, stage, treatment history and the clinical question being addressed. NCI recommends discussing whether testing is appropriate with the healthcare team.
What is a cancer biomarker?
A cancer biomarker is a measurable gene, protein or other biological characteristic that can provide information about a tumor. Some biomarkers can help doctors determine whether particular treatments may be appropriate.
Is targeted therapy better than chemotherapy?
Not automatically. Targeted therapy may be highly useful for cancers with specific actionable targets, while chemotherapy remains an important treatment for many cancers. Doctors select treatment based on the cancer and patient’s individual circumstances.
Can precision medicine cure cancer?
Precision medicine does not guarantee a cure. It can help identify treatments that may work for selected patients, but response varies and cancer can develop resistance.
What is liquid biopsy?
Liquid biopsy is a testing approach that looks for cancer-related molecular material in blood or another body fluid. It may be useful in selected situations but does not replace every tissue biopsy.
Can precision medicine be used in India?
Yes. Precision oncology and molecular testing are increasingly relevant to cancer care in India, but availability of testing, treatments and specialist interpretation varies between healthcare settings. Patients should discuss appropriate options with their oncology team.
How much does genomic testing for cancer cost in India?
Costs vary substantially depending on the type of test, laboratory, number of genes analyzed and clinical indication. Patients should obtain a current quotation and ask whether the test is clinically necessary before proceeding.
Can genomic testing find inherited cancer risk?
Some genetic tests can identify inherited variants, but tumor biomarker testing and inherited genetic testing are different. If there is a strong family history of cancer, discuss whether hereditary cancer evaluation is appropriate.
Can precision medicine identify a clinical trial?
It can sometimes help identify clinical trials designed around specific molecular alterations. Trial eligibility depends on the study’s inclusion criteria and the patient’s overall clinical condition.
What happens if my genomic test finds no actionable mutation?
It does not mean that treatment options are unavailable. Standard cancer treatments can remain appropriate, and the oncology team will consider the cancer type, stage, previous treatments and other clinical information.
Conclusion: From Discovery to More Informed Cancer Care
The rise of precision cancer medicine represents one of the most important shifts in modern oncology.
Cancer is not one disease. Even tumors that appear similar under a microscope can have different molecular characteristics. Advances in biomarker testing, genomic profiling, targeted therapy and immunotherapy are helping researchers and clinicians understand these differences more clearly.
But precision medicine should be understood realistically.
It is not a guaranteed cure. It does not eliminate the need for surgery, radiation or chemotherapy. And not every genetic change found in a tumor has a treatment attached to it.
Its real strength lies in helping doctors answer a more specific question:
“What does this particular cancer need in order to grow, and is there an evidence-based way to target it?”
From the laboratory bench to the pathology report, from genomic testing to clinical trials, precision oncology connects scientific discovery with patient care.
For patients in India and elsewhere, the most important step is not simply getting the biggest genomic test available. It is having the right test, interpreted by the right clinical team, for the right medical decision.
The future of cancer treatment may become increasingly precise—but the human side of cancer care will remain just as important.
Better information can lead to better decisions. And better decisions are where precision cancer medicine truly begins.
